After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers.
Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.
London-based sustainable technologies company Johnson Matthey has partnered with biotechnology firm Basecamp Research to adopt more sustainable, bio-based catalysts.
Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...
Seekyo, a startup biotechnology company specializing in the development of ‘smart chemotherapy’ drugs that limit harmful side effects, has raised in excess of €650,000 (US$775K) in bridge funding.
Halozyme Therapeutics announced that a subcutaneous formulation of trastuzumab created with Halozyme’s technology, for the treatment of breast cancer, has received approval from Health Canada.
Hepregen has agreed to provide US CRO QPS Holdings with long-term liver cell models to aid its offerings in drug metabolism and pharmacokinetic (DMPK) services.
The recently-formed Advanced Biosciences unit of Rohm and Haas has
introduced the first product in a new line of functionalised resin
systems for the immobilisation of biocatalytic enzymes at the CphI
meeting in Frankfurt, Germany.